Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 2

171MO - Inflammatory profiling of individuals with germline TP53 mutations (gTP53m) and its relationship to subsequent cancer development


12 May 2023


Mini Oral session 2


Secondary Prevention/Screening

Tumour Site




Annals of Oncology (2023) 8 (1suppl_4): 101222-101222. 10.1016/esmoop/esmoop101222


T. BEN AHMED1, M. Fidelle2, I. Lahmar2, A. Mallard de La Varende2, E. Karamouza2, L. Zitvogel2, V. Goldbarg2, O. Caron2, S. Delaloge3

Author affiliations

  • 1 Gustave Roussy - Cancer Campus, Villejuif/FR
  • 2 Gustave Roussy, Villejuif/FR
  • 3 Institut Gustave Roussy, Villejuif/FR


This content is available to ESMO members and event participants.

Abstract 171MO


Individuals with gTP53m have nearly 24 times higher incidence of any cancer than the general population, of which breast cancer (BC) comes first. Beside prophylactic mastectomy, no preventative measures are currently available. Nothing or very little is known regarding the role of immune and inflammatory factors. We aimed to search for predictors of the development of new subsequent cancers (NSC) among inflammatory and immune cytokines, in patients (pts) with gTP53m from the prospective LIFSCREEN MRI screening trial (NCT01464086).


All pts with gTP53m who entered the LIFSCREEN trial at Gustave Roussy 11/2011 - 12/2014, with frozen serum samples available were eligible. We analysed inflammatory cytokines and chemokines on samples collected sequentially at accrual month (M) 0 and at M12 using multiplex immunoassay of serum analytes (Bio-Plex Pro™ 40-plex, Bio-Rad). Primary objective was potential associations between M0 and M12 biomarkers and the incidence of any NSC. We used Wilcoxon-Mann Whitney tests and logistic regressions.


Among 107 pts, 42 had serum stored and were eligible. Median age 35.5 (7-67), 67% females. Median follow-up 100 months (95% CI 83-117). 24 pts (57%) had already had cancer before entering the study, of which 7 BC. 11 NSC were diagnosed. At M0, a Th1-like profile (high serum IL-2 (>2 pg/ml) (p=0.03; overall) and CXCL9 levels (>50 pg/ml) (p=0.01; without history of cancers)) was associated with the incidence of NSC. In logistic regression, the Th1 CXCL9 and CXCL10 chemokines were associated with a higher probability of NSC (p=0.03 and 0.04, respectively). At M12, high levels of the follicular T helper cell CXCL13 (>25 pg/ml) chemokine were protective against NSC (p=0.04). Individuals with a significant drop between M0 and M12 of neutrophil and T cell-chemoattracting factors (such as CXCL1 and IFNg/CXCL16 respectively) did not develop cancer.


This exploratory study identifies a disbalance between Th1 and TFH soluble markers in Li Fraumeni deemed to experience additional neoplasia among pts carrying gTP53m. These findings warrant further validation and could be actionable for cancer interception.

Legal entity responsible for the study

Gustave Roussy, Department of Cancer Medicine.


The LIFSCREEN clinical trial (NCT01464086) was funded by the French Ligue Contre le Cancer. Tarek Ben Ahmed was funded by the grant for DUERTECC (European University Diploma in Translational and Clinical Cancer Research) and by Odyssea for the conduct of the present work. Experiments were conducted as part of the ONCOBIOME consortium project, a European Commission Horizon 2020-funded project (lead Laurence Zitvogel, www.oncobiome.eu).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.